Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:16 PM ET 8-K
Leadership Change Ingles Markets Inc IMKTA

Ingles Markets Leadership Change

Ingles Markets appointed Kevin Hefner to its Board of Directors to fill a vacancy created by the departure of Brenda S. Tudor. Mr. Hefner will also serve on the Audit Committee and as chairman of the Compensation and Governance Committee. Additionally, the company updated its bylaws and set the date for its 2027 Annual Meeting of Shareholders for March 2, 2027.

Counterparty
Kevin Hefner
4:16 PM ET 8-K
Shareholder Meeting Glucotrack, Inc. GCTK

Glucotrack Shareholder Meeting

Glucotrack held a special meeting of stockholders on September 11, 2026, where shareholders approved the full issuance of common stock related to an equity line of credit with White Lion Capital and senior secured convertible promissory notes. Additionally, the company amended a securities purchase agreement with a PIPE purchaser to ensure warrant exercises comply with Nasdaq Listing Rule 5635(d) following stockholder approval.

4:16 PM ET Form 4
Insider Selling Phinia Inc. PHIN

Phinia VP and Chief Tech. Officer Todd L. Anderson Sells $203K of Stock

Todd L. Anderson, VP and Chief Tech. Officer, sold 3,056 shares of Phinia Inc. at $66.41 a share, worth $203K in total on Sep 11, 2026. Shares held after the trade: 26,736 (-10.3%).

Value
$203K
Shares
3,056
Price
$66.41
Role
VP and Chief Tech. Officer
Holding change
-10.3%
Trade date
Sep 11, 2026
4:15 PM ET 8-K
M&A Deal Enova International, Inc. ENVA

Enova International M&A Deal with Grasshopper Bancorp, Inc.

Enova International has withdrawn its regulatory applications with the OCC and Federal Reserve for the proposed acquisition of Grasshopper Bancorp, Inc. The company cited a lack of clear regulatory standards for nonbanks and stated its future growth does not depend on becoming a bank. Enova reaffirmed its 2026 financial guidance and announced plans to accelerate share repurchases for the remainder of the year.

Counterparty
Grasshopper Bancorp, Inc.
Earnings call
Jun 30, 2027, 5:00 PM ET
4:15 PM ET Form 4
Insider Selling Hinge Health, Inc. HNGE

Hinge Health Director Gabriel M.i. Mecklenburg Sells $22.2M of Stock

Gabriel M.i. Mecklenburg, Director, sold 250,000 shares of Hinge Health, Inc. at $87.02 to $90.46 a share (average $88.97) in 5 transactions, worth $22.2M in total on Sep 11, 2026. Shares held after the trade: 0 (-100.0%).

Value
$22.2M
Shares
250,000
Average price
$88.97
Role
Director
Holding change
-100.0%
Trade date
Sep 11, 2026
4:15 PM ET Form 4
Insider Buying Angel Studios, Inc. ANGX

Angel Studios Insider Steven I. Sarowitz Buys $473K of Stock

Steven I. Sarowitz bought 88,647 shares of Angel Studios, Inc. at $5.33 a share, worth $473K in total on Sep 11, 2026. Shares held after the trade: 1,329,488 (+7.1%).

Value
$473K
Shares
88,647
Price
$5.33
Holding change
+7.1%
Trade date
Sep 11, 2026
4:14 PM ET 8-K
Nasdaq/NYSE Compliance Notice Longeveron Inc. LGVN

Longeveron Nasdaq/NYSE Compliance Notice

Longeveron Inc. has regained compliance with Nasdaq's $1.00 minimum bid price requirement after its Class A common stock maintained a closing price of at least $1.00 for 10 consecutive business days. The company had previously been under a deficiency notice since September 2025 and was granted two 180-day extension periods to resolve the issue. Nasdaq has officially closed the matter, securing the company's continued listing on The Nasdaq Capital Market.

Counterparty
Nasdaq
4:13 PM ET 8-K
Financial Results Dave & Buster's Entertainment, Inc. PLAY

Dave & Buster's Entertainment Financial Results

Dave & Buster's reported second quarter 2026 revenue of $544.1 million, a 2.4% decrease year-over-year, with comparable store sales down 2.9%. The company swung to a net loss of $12.5 million compared to net income of $11.4 million in the prior year period. Despite the loss, management highlighted momentum in their 'Back-to-Basics' strategy and improved sales trends in July and the early third quarter.

Term
Q2 2026
Earnings call
Sep 14, 2026, 7:00 PM ET

“We are energized by the obvious, actionable, and enormous opportunities ahead for Dave & Buster’s and Main Event. Our Back-to-Basics strategy is gaining momentum with enhanced executional urgency. We are experiencing ongoing growth in food and beverage sales as well as in Special Events sales. The same store sales of our remodels continue to outperform the system. Further, we improved overall same store sales in July, and saw continued improvement in overall same store sales during the third quarter to date. We are laser focused on returning to same-store sales and EBITDA growth, sharpening our margin management with cost saving initiatives, generating significant free cash flow, and delivering meaningful shareholder value. I have tremendous confidence in the direction of our business and am excited about what we will accomplish together as we shape the future of our company.”

Darin Harper, Chief Executive Officer
4:12 PM ET 8-K
Executive Compensation Rare Element Resources Ltd REEMF

Rare Element Resources Executive Compensation

Rare Element Resources Ltd. appointed Josef Bilant as Chief Operating Officer, effective October 5, 2026. Mr. Bilant's compensation package includes an annual base salary of $330,000, a $99,000 sign-on bonus, and eligibility for an annual performance bonus with a 30% target of his base salary.

Counterparty
Josef Bilant
4:12 PM ET Form 4
Insider Selling Western New England Bancorp, Inc. WNEB

Western New England Bancorp SVP & Chief Risk Officer Leo R. Sagan Jr. Sells $47.5K of Stock

Leo R. Sagan Jr., SVP & Chief Risk Officer, sold 3,490 shares of Western New England Bancorp, Inc. at $13.61 a share, worth $47.5K in total on Sep 10, 2026. Shares held after the trade: 59,264 (-5.6%).

Value
$47.5K
Shares
3,490
Price
$13.61
Role
SVP & Chief Risk Officer
Holding change
-5.6%
Trade date
Sep 10, 2026
4:11 PM ET 8-K
Capital Raise PDS Biotechnology Corp PDSB

PDS Biotechnology Capital Raise of $11.3M

PDS Biotechnology completed the initial closing of a PIPE financing led by Nant Capital, raising $11.3 million in gross proceeds through the sale of common stock and warrants. The company also announced a contingent milestone closing for an additional $11 million and appointed Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors. Proceeds will be used to repay $4.6 million in debt to Yorkville and advance the PDS0301 clinical program.

Value
$11.3M
Counterparty
Nant Capital, LLC
4:11 PM ET 8-K
Other 8-K Filing First Citizens Bancshares Inc FCNCA

First Citizens Bancshares Other 8-K Filing

First Citizens BancShares filed an 8-K reporting material modifications to the rights of security holders and amendments to its Articles of Incorporation or Bylaws. These items typically indicate changes to the company's capital structure, such as the authorization of new classes of stock or changes to shareholder voting rights. Without specific document text, the filing represents a structural corporate governance update.

4:11 PM ET 8-K
Other 8-K Filing Sionna Therapeutics, Inc. SION

Sionna Therapeutics Other 8-K Filing

Sionna Therapeutics approved a restructuring plan to focus resources on its SION-451 and SION-2222 dual combination program, involving a 46% workforce reduction and the wind-down of its SION-719 add-on program. The company expects to incur approximately $6.4 million in restructuring charges, primarily for severance and contract close-out costs, while extending its cash runway into the second half of 2029. Additionally, Chief Business Officer Caroline Stark Beer was terminated without cause as part of the reorganization.

Earnings call
Sep 14, 2026, 4:30 PM ET
4:11 PM ET 8-K
M&A Deal Magnolia Oil & Gas Corp MGY

Magnolia Oil & Gas Signs $2.57B M&A Deal with WildFire Energy I LLC

Magnolia Oil & Gas Corporation completed its acquisition of WildFire Energy I LLC for $2.57 billion in cash and 32,203,000 shares of Class A common stock. As part of the transaction, Magnolia assumed $600 million in 7.500% Senior Notes due 2029 and merged the target entities into its operating subsidiary.

Value
$2.57B
Counterparty
WildFire Energy I LLC
4:10 PM ET Form 4
Insider Selling Curbline Properties Corp. CURB

Curbline Properties Director Alexander Otto Sells $69.2K of Stock

Alexander Otto, Director, sold 2,344 shares of Curbline Properties Corp. at $29.51 a share, worth $69.2K in total on Sep 10, 2026. Shares held after the trade: 6,550,914 (-0.0%).

Value
$69.2K
Shares
2,344
Price
$29.51
Role
Director
Holding change
-0.0%
Trade date
Sep 10, 2026
4:10 PM ET 8-K
Loan & Debt Burford Capital Ltd BUR

Burford Capital $300M Debt Financing

Burford Capital's subsidiary announced a private offering of $300 million in senior secured notes due 2029. The proceeds are intended to fund the redemption of $400 million in outstanding 6.250% senior notes due 2028 as part of a broader de-leveraging strategy.

Value
$300M
Term
through 2029
4:09 PM ET Form 4
Insider Selling Lithia Motors Inc LAD

Lithia Motors Insider Congdon Stacy Loretz Sells $27.8K of Stock

Congdon Stacy Loretz sold 75 shares of Lithia Motors Inc at $370.73 a share, worth $27.8K in total on Sep 11, 2026. Shares held after the trade: 2,300 (-3.2%).

Value
$27.8K
Shares
75
Price
$370.73
Holding change
-3.2%
Trade date
Sep 11, 2026
4:09 PM ET Form 4
Insider Selling La-Z-Boy Inc LZB

La-Z-Boy President, Retail Robert Sundy II Sells $154K of Stock

Robert Sundy II, President, Retail, sold 5,000 shares of La-Z-Boy Inc at $30.85 a share, worth $154K in total on Sep 10, 2026. Shares held after the trade: 59,297 (-7.8%).

Value
$154K
Shares
5,000
Price
$30.85
Role
President, Retail
Holding change
-7.8%
Trade date
Sep 10, 2026
4:09 PM ET 8-K
Investor Presentation Boot Barn Holdings, Inc. BOOT

Boot Barn Holdings Investor Presentation

Boot Barn Holdings announced its participation in the Goldman Sachs Global Consumer and Retail Conference and the Piper Sandler Growth Frontiers Conference. The company provided a business update noting 2% same-store sales growth in fiscal August and September to date, and reaffirmed its Q2 guidance while expecting total sales and EPS to hit the high end of previously announced ranges.

4:08 PM ET 8-K
M&A Deal Veracyte, Inc. VCYT

Veracyte Signs $150M M&A Deal with Convergent Genomics Inc.

Veracyte completed the acquisition of Convergent Genomics, a genomic diagnostics company focused on bladder cancer, for $150 million in upfront cash plus up to $30 million in milestone-based payments. The deal adds the UroAmp urinary tumor DNA (utDNA) technology to Veracyte's urology portfolio, with a commercial launch expected in late 2028.

Value
$150M
Counterparty
Convergent Genomics Inc.

“UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte’s ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum.”

Marc Stapley, Veracyte’s chief executive officer

“We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”

Brian Slingerland, chief executive officer, Convergent Genomics
4:07 PM ET 8-K
Clinical Trial Data Contineum Therapeutics, Inc. CTNM

Contineum Therapeutics Clinical Trial Data

Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder did not meet its primary efficacy endpoint of improvement in the MADRS total score. The drug candidate, which is being developed under a global license agreement with Johnson & Johnson, was well-tolerated with no new safety signals. Johnson & Johnson is currently evaluating the full data set, including exploratory endpoints, to determine the next steps for the program.

Counterparty
Johnson & Johnson
4:07 PM ET Form 4
Insider Selling Diamondback Energy, Inc. FANG

Diamondback Energy Insider Travis D. Stice Sells $15.3M of Stock

Travis D. Stice sold 75,000 shares of Diamondback Energy, Inc. at $204.31 a share, worth $15.3M in total on Sep 11, 2026. Shares held after the trade: 49,727 (-60.1%).

Value
$15.3M
Shares
75,000
Price
$204.31
Holding change
-60.1%
Trade date
Sep 11, 2026
4:07 PM ET Form 4
Insider Buying Jushi Holdings Inc. JUSH

Jushi Holdings Insider Denis J. Arsenault Buys $69.6K of Stock

Denis J. Arsenault bought 118,034 shares of Jushi Holdings Inc. at $0.59 a share, worth $69.6K in total on Sep 3, 2026. Shares held after the trade: 7,795,933 (+1.5%).

Value
$69.6K
Shares
118,034
Price
$0.5900
Holding change
+1.5%
Trade date
Sep 3, 2026
4:07 PM ET 8-K
Other 8-K Filing Teva Pharmaceutical Industries Ltd TEVA

Teva Pharmaceutical Industries Other 8-K Filing

Teva Pharmaceutical Industries Ltd. has transitioned its listing on the New York Stock Exchange from American depositary shares (ADSs) to ordinary shares under the existing ticker 'TEVA'. The company's ADS program was terminated effective September 14, 2026, with each ADS exchanged for one ordinary share on a one-for-one basis.

4:06 PM ET 8-K
Business Update 60 Degrees Pharmaceuticals, Inc. SXTP

60 Degrees Pharmaceuticals Business Update

60 Degrees Pharmaceuticals submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher (CNPV) for its ARAKODA (tafenoquine) efficacy supplement for babesiosis. The company aims to submit a supplemental New Drug Application (sNDA) in early 2027, potentially making it the first FDA-approved treatment for the tick-borne disease. An interim analysis of its randomized controlled trial is scheduled for October 1, 2026.

Counterparty
FDA
4:06 PM ET 8-K
Loan & Debt Oxford Square Capital Corp. OXSQ

Oxford Square Capital $15M Debt Financing with U.S. Bank Trust Company, National Association

Oxford Square Capital Corp. has elected to redeem $15.0 million in aggregate principal amount of its 5.50% Notes due 2028. The redemption is scheduled for October 14, 2026, at a price of $25 per note plus accrued and unpaid interest. This partial redemption reduces the outstanding principal of these notes from $80.5 million to $65.5 million.

Value
$15M
Counterparty
U.S. Bank Trust Company, National Association
4:06 PM ET 8-K
Leadership Change Inmune Bio, Inc. INMB

Inmune Bio Leadership Change

INmune Bio, Inc. has expanded its Board of Directors to seven members and appointed R. Duane Clark II and James Sapirstein as independent directors. Mr. Clark currently leads Sanofi's U.S. Rare Diseases business, while Mr. Sapirstein is the CEO of Cocrystal Pharma and has extensive experience in biopharma business development and licensing. These appointments are intended to strengthen the company's commercialization planning for Ebstrocel and its strategic partnering capabilities.

4:06 PM ET 8-K
Investor Presentation Scienture Holdings, Inc. SCNX

Scienture Holdings Investor Presentation

Scienture Holdings, Inc. has posted a revised investor presentation to its corporate website and filed it as an exhibit to this 8-K. The company intends to use the presentation in upcoming meetings with analysts and potential investors to discuss its projects, financial performance, and growth opportunities.

4:06 PM ET 8-K
Financial Results Benitec Biopharma Inc. BNTC

Benitec Biopharma Financial Results

Benitec Biopharma reported financial results for the fiscal year ended June 30, 2026, ending the period with approximately $180 million in cash. The company provided a clinical update on its BB-301 program for OPMD-related dysphagia, noting that Cohort 2 is fully enrolled and a pivotal study is planned for initiation in mid-2027 following a Type C meeting with the FDA.

Term
FY2026

“This has been an important year of clinical execution for Benitec and for the continued development of BB-301. Over the course of the year, we completed the follow-up of all six patients in Cohort 1 and fully enrolled Cohort 2, while continuing the regulatory interactions required to prepare BB-301 for advancement into a pivotal trial.”

Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer

“The consistency and durability of the clinical benefit observed to date, together with the discussions we have had with the FDA regarding pivotal study plans, continue to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia.”

Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer
4:06 PM ET 8-K
Reverse Stock Split Nextnrg, Inc. NXXT

Nextnrg Reverse Stock Split

NextNRG, Inc. implemented a 1-for-10 reverse stock split of its common stock effective September 14, 2026. The split reduced the number of outstanding shares from approximately 168.4 million to 16.8 million to adjust the per-share trading price on the Nasdaq Capital Market.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.